Key result
Type 2 diabetes linked to ~40% lower clopidogrel active metabolite exposure and higher platelet reactivity.
Why the study?
Patients with diabetes mellitus exhibit an impaired response to clopidogrel, which may contribute to an increased risk of recurrent atherothrombotic events, but the underlying mechanisms have not been fully elucidated.
Does type 2 diabetes mellitus impair pharmacokinetic exposure to clopidogrel's active metabolite and pharmacodynamic platelet inhibition after a 600-mg clopidogrel loading dose in patients with stable coronary artery disease?
Observational (n=60)
Does type 2 diabetes mellitus impair pharmacokinetic exposure to clopidogrel's active metabolite and pharmacodynamic platelet inhibition after a 600-mg clopidogrel loading dose in patients with stable coronary artery disease?
Impaired clopidogrel-mediated platelet inhibition in patients with type 2 diabetes and coronary artery disease is primarily driven by a ~40% reduction in active metabolite pharmacokinetic exposure rather than intrinsic P2Y12 receptor signaling defects.
Answers are grounded in this paper and cite their sources.
May underlie clopidogrel hyporesponsiveness in diabetes; hypothesis-generating and should not yet change practice.
Background Several studies have shown that patients with diabetes mellitus (DM) exhibit an impaired response to clopidogrel. This may contribute to their increased risk of recurrent atherothrombotic events, despite the use of dual-antiplatelet therapy. The mechanisms for impaired clopidogrel response in DM patients have not been fully elucidated. Objectives The aim of this study was to explore the mechanisms for impaired clopidogrel-mediated platelet inhibition in patients with DM using a comprehensive methodological approach embracing both pharmacokinetic (PK) and pharmacodynamic (PD) assessments as well as ex vivo and in vitro investigations. Methods Patients (DM, n = 30; non-DM, n = 30) with stable coronary artery disease taking aspirin 81 mg/day and P2Y12 antagonist naive were enrolled. Blood was collected before and at various times (0.5, 1, 2, 4, 6, and 24 h) after a 600-mg loading dose of clopidogrel. PD assessments included vasodilator-stimulated phosphoprotein, light transmission aggregometry, and VerifyNow P2Y12 ex vivo, before and after dosing and following in vitro incubation with escalating concentrations (1, 3, and 10 μM) of clopidogrel's active metabolite (Clop-AM). Exposure to Clop-AM was also determined. Results PD assessments consistently showed that during the overall 24-h study time course, residual platelet reactivity was higher in DM patients compared with non-DM patients. In vitro incubation with Clop-AM revealed altered functional status of the P2Y12 signaling pathway in DM platelets as measured by vasodilator-stimulated phosphoprotein, but not with other PD assays. Clop-AM exposure was ∼40% lower in DM patients than in non-DM patients. Conclusions The present study suggests that among DM patients, impaired P2Y12 inhibition mediated by clopidogrel is largely attributable to attenuation of clopidogrel's PK profile. This is characterized by lower plasma levels of Clop-AM over the sampling time course in DM patients compared with non-DM patients and only modestly attributed to altered functional status of the P2Y12 signaling pathway.
No takes yet. Share an insight, caveat, or question.
Angiolillo et al. (2014) conducted an observational in Stable coronary artery disease with or without type 2 diabetes mellitus (n=60). Type 2 diabetes mellitus (evaluated following 600-mg clopidogrel loading dose) vs. Non-diabetes mellitus patients receiving 600-mg clopidogrel loading dose was evaluated on Pharmacodynamic platelet reactivity and pharmacokinetic exposure to clopidogrel's active metabolite (Clop-AM) over 24 hours (~40% lower Clop-AM exposure in DM patients). Patients with type 2 diabetes had higher residual platelet reactivity and ~40% lower exposure to clopidogrel's active metabolite over 24 hours after a 600-mg loading dose than non-diabetic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: